Publications 2024

Hektoen HH, Tsuruda KM, Fjellbirkeland L, Nilssen Y, Brustugun OT, Andreassen BK (2024)
Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study
Br J Cancer (in press)
DOI 10.1038/s41416-024-02895-1, PubMed 39489879

Lærum D, Strand TE, Brustugun OT, Gallefoss F, Falk R, Durheim MT, Fjellbirkeland L (2024)
Evaluation of sex inequity in lung-cancer-specific survival
Acta Oncol, 63, 343-350
DOI 10.2340/1651-226X.2024.27572, PubMed 38751329

Nilssen Y, Brustugun OT, Fjellbirkeland L, Grønberg BH, Haram PM, Helbekkmo N, Helland Å, Wahl SGF, Aanerud M, Solberg S (2024)
Small Cell Lung Cancer in Norway: Patterns of Care by Health Region and Survival Trends
Clin Lung Cancer, 25 (5), e221-e228.e3
DOI 10.1016/j.cllc.2024.04.002, PubMed 38692990

Nilssen Y, Brustugun OT, Fjellbirkeland L, Helland Å, Møller B, Wahl SGF, Solberg S (2024)
Distribution and characteristics of malignant tumours by lung lobe
BMC Pulm Med, 24 (1), 106
DOI 10.1186/s12890-024-02918-w, PubMed 38439038

Publications 2023

Gouliaev A, Rasmussen TR, Malila N, Fjellbirkeland L, Löfling L, Jakobsen E, Dalton SO, Christensen NL (2023)
Lung cancer registries in Denmark, Finland, Norway and Sweden: a comparison and proposal for harmonization
Acta Oncol, 62 (1), 1-7
DOI 10.1080/0284186X.2023.2172687, PubMed 36718556

Rakaee M, Andersen S, Giannikou K, Paulsen EE, Kilvaer TK, Busund LR, Berg T, Richardsen E, Lombardi AP, Adib E, Pedersen MI, Tafavvoghi M, Wahl SGF, Petersen RH, Bondgaard AL, Yde CW, Baudet C, Licht P, Lund-Iversen M, Grønberg BH, Fjellbirkeland L, Helland Å, Pøhl M, Kwiatkowski DJ, Donnem T (2023)
Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial
Ann Oncol, 34 (7), 578-588
DOI 10.1016/j.annonc.2023.04.005, PubMed 37100205

Publications 2022

Solberg S, Nilssen Y, Terje Brustugun O, Magnus Haram P, Helland Å, Møller B, Strand TE, Gyrid Freim Wahl S, Fjellbirkeland L (2022)
Concordance between clinical and pathology TNM-staging in lung cancer
Lung Cancer, 171, 65-69
DOI 10.1016/j.lungcan.2022.07.014, PubMed 35926242

Publications 2021

Laerum D, Brustugun OT, Gallefoss F, Falk R, Strand TE, Fjellbirkeland L (2021)
Factors associated with delayed treatment initiation in an unselected cohort of patients with small-cell lung cancer
Cancer Treat Res Commun, 29, 100477
DOI 10.1016/j.ctarc.2021.100477, PubMed 34700140

Publications 2020

Brustugun OT, Sorhaug S, Gronberg BH, Aanerud M, Al-Zubayidy MMZ, Fjellbirkeland L, Helland A, Berg J, Andreassen B, Paulsen EE, Haram PM, Ashraf H, Wahl SGF (2020)
Lung cancer: Improved prognosis presents capacity challenges
Tidsskr. Nor. Laegeforen., 140 (5), 432-434

Brustugun OT, Sørhaug S, Grønberg BH, Aanerud M, Al-Zubayidy MMZ, Fjellbirkeland L, Helland Å, Berg J, Andreassen B, Paulsen EE, Haram PM, Ashraf H, Wahl SGF (2020)
[Lung cancer: Improved prognosis results in capacity challenges]
Tidsskr Nor Laegeforen, 140 (5)
DOI 10.4045/tidsskr.20.0014, PubMed 32238965

Laerum D, Brustugun OT, Gallefoss F, Falk R, Strand TE, Fjellbirkeland L (2020)
Reduced delays in diagnostic pathways for non-small cell lung cancer after local and National initiatives
Cancer Treat Res Commun, 23, 100168 (in press)
DOI 10.1016/j.ctarc.2020.100168, PubMed 32028190

Thøgersen H, Møller B, Åsli LM, Bhargava S, Kvåle R, Fjellbirkeland L, Robsahm TE, Aaserud S, Babigumira R, Larsen IK (2020)
Waiting times and treatment following cancer diagnosis: comparison between immigrants and the Norwegian host population
Acta Oncol, 59 (4), 376-383
DOI 10.1080/0284186X.2019.1711167, PubMed 31920119

Publications 2019

Solberg S, Nilssen Y, Brustugun OT, Grimsrud TK, Haram PM, Helbekkmo N, Helland Å, Hjelde HH, Jakobsen B, Møller B, Petersen M, Strand TE, Wahl SGF, Aanerud M, Fjellbirkeland L (2019)
Increase in curative treatment and survival of lung cancer in Norway 2001-2016
Eur J Epidemiol, 34 (10), 951-955
DOI 10.1007/s10654-019-00536-z, PubMed 31313073

Publications 2018

Brustugun OT, Grønberg BH, Fjellbirkeland L, Helbekkmo N, Aanerud M, Grimsrud TK, Helland Å, Møller B, Nilssen Y, Strand TE, Solberg SK (2018)
Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016
Lung Cancer, 122, 138-145
DOI 10.1016/j.lungcan.2018.06.003, PubMed 30032822

Fjellbirkeland L (2018)
LUNG CANCER SCREENING
Tidsskr. Nor. Laegeforen., 138 (15), 1470

Publications 2015

Berg J, Fjellbirkeland L, Suhrke P, Jebsen P, Lund-Iversen M, Kleinberg L, Helgeland L, Brustugun OT, Helland Å (2015)
EGFR mutation testing of lung cancer patients - Experiences from Vestfold Hospital Trust
Acta Oncol, 55 (2), 149-55
DOI 10.3109/0284186X.2015.1062537, PubMed 26313507

Fjellbirkeland L (2015)
Crash course - Respiratory system
Tidsskr. Nor. Laegeforen., 135 (5), 459
DOI 10.4045/tidsskr.14.1485

Nilssen Y, Strand TE, Fjellbirkeland L, Bartnes K, Brustugun OT, O'Connell DL, Yu XQ, Møller B (2015)
Lung cancer treatment is influenced by income, education, age and place of residence in a country with universal health coverage
Int J Cancer, 138 (6), 1350-60
DOI 10.1002/ijc.29875, PubMed 26421593

Nilssen Y, Strand TE, Fjellbirkeland L, Bartnes K, Møller B (2015)
Lung cancer survival in Norway, 1997-2011: from nihilism to optimism
Eur Respir J, 47 (1), 275-87
DOI 10.1183/13993003.00650-2015, PubMed 26541525

Publications 2012

Brustugun OT, Helland Å, Fjellbirkeland L, Kleinberg L, Ariansen S, Jebsen P, Scott H, Dønnem T, Bremnes R, Berg T, Grønberg BH, Dai HY, Wahl SG, Mangseth K, Helgeland L (2012)
[Mutation testing for non-small-cell lung cancer]
Tidsskr Nor Laegeforen, 132 (8), 952-5
DOI 10.4045/tidsskr.11.1017, PubMed 22562326

Lund-Iversen M, Kleinberg L, Fjellbirkeland L, Helland Å, Brustugun OT (2012)
Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations
J Thorac Oncol, 7 (9), 1471-3
DOI 10.1097/JTO.0b013e3182614a9d, PubMed 22895145

Publications 2005

Kim KU, Wilson SM, Abayasiriwardana KS, Collins R, Fjellbirkeland L, Xu Z, Jablons DM, Nishimura SL, Broaddus VC (2005)
A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance
Am J Respir Cell Mol Biol, 33 (6), 541-8
DOI 10.1165/rcmb.2004-0355OC, PubMed 16123394

Publications 2003

Fjellbirkeland L, Cambier S, Broaddus VC, Hill A, Brunetta P, Dolganov G, Jablons D, Nishimura SL (2003)
Integrin alphavbeta8-mediated activation of transforming growth factor-beta inhibits human airway epithelial proliferation in intact bronchial tissue
Am J Pathol, 163 (2), 533-42
DOI 10.1016/s0002-9440(10)63681-4, PubMed 12875973

Publications 2002

Mu D, Cambier S, Fjellbirkeland L, Baron JL, Munger JS, Kawakatsu H, Sheppard D, Broaddus VC, Nishimura SL (2002)
The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1
J Cell Biol, 157 (3), 493-507
DOI 10.1083/jcb.200109100, PubMed 11970960

Publications 1998

Fjellbirkeland L, Bjerkvig R, Laerum OD (1998)
Non-small-cell lung carcinoma cells invade human bronchial mucosa in vitro
In Vitro Cell Dev Biol Anim, 34 (4), 333-40
DOI 10.1007/s11626-998-0010-4, PubMed 9590507

Fjellbirkeland L, Laerum OD, Eide GE, Bjerkvig R (1998)
Invasiveness by lacZ transfected non-small-cell lung cancer cells into human bronchial tissues in vitro
Lung Cancer, 21 (1), 7-19
DOI 10.1016/s0169-5002(98)00037-3, PubMed 9792049

Vatne V, Fjellbirkeland L, Litlekalsoey J, Hoestmark J (1998)
Nonadheshive stationary organ culture of normal human urinary bladder mucosa
Anticancer Res, 18 (6A), 3979-83
PubMed 9891434

Vatne V, Fjellbirkeland L, Litlekalsoey J, Hoestmark J (1998)
A human in vitro model of bladder tumour cell invasion
Anticancer Res, 18 (6A), 3985-9
PubMed 9891435

Vatne V, Fjellbirkeland L, Litlekalsoey J, Hoestmark J (1998)
Nonadhesive stationary organ culture of normal human urinary bladder mucosa
Anticancer Res., 18 (6A), 3979-3983

Publications 1996

Fjellbirkeland L, Bjerkvig R, Steinsvåg SK, Laerum OD (1996)
Nonadhesive stationary organ culture of human bronchial mucosa
Am J Respir Cell Mol Biol, 15 (2), 197-206
DOI 10.1165/ajrcmb.15.2.8703475, PubMed 8703475

Publications 1995

Fjellbirkeland L, Bjerkvig R, Laerum OD (1995)
Tumour fragment spheroids from human non-small-cell lung cancer maintained in organ culture
Virchows Arch, 426 (2), 169-78
DOI 10.1007/BF00192639, PubMed 7757288

FJELLBIRKELAND L, BJERKVIG R, LAERUM OD (1995)
TUMOR FRAGMENT SPHEROIDS FROM HUMAN NON-SMALL-CELL LUNG-CANCER MAINTAINED IN ORGAN-CULTURE
Virchows Arch. Int. J. Pathol., 426 (2), 169-178

Fjellbirkeland L, Gulsvik A, Walløe A (1995)
[Swimming-induced asthma]
Tidsskr Nor Laegeforen, 115 (17), 2051-3
PubMed 7644982

Fjellbirkeland L, Gulsvik A, Walløe A (1995)
Svømmeindusert astma
In Tidsskrift for Den norske legeforening, Foreningen, Oslo, 115(1995)nr. 17, S. 2051-2053
BIBSYS 952650088

Hansen G, Andrew M, Bjermer L, Brørs O, Fjellbirkeland L, Johansen B, Langhammer A, Maehlumshagen G, Nguyen KN, Røyset P (1995)
[Guidelines for understanding and treating chronic obstructive lung diseases. Institute for Pharmacotherapy]
Tidsskr Nor Laegeforen, 115 (6), 710-3
PubMed 7900132

Publications 1994

Fjellbirkeland L, Gulsvik A, Palmer JB (1994)
The efficacy and tolerability of inhaled salmeterol and individually dose-titrated, sustained-release theophylline in patients with reversible airways disease
Respir Med, 88 (8), 599-607
DOI 10.1016/s0954-6111(05)80008-3, PubMed 7991885

Publications 1990

Fjellbirkeland L, Gulsvik A (1990)
[Methods for administration of anti-asthma inhalation drugs]
Tidsskr Nor Laegeforen, 110 (16), 2092-5
PubMed 2368076